(AbbVie) Oct 17, 2018 - If granted, IMBRUVICA plus obinutuzumab could become the first chemotherapy-free, anti-CD20 combination approved by the FDA for first-line CLL treatment. The submission is based on positive results from the Phase 3 iLLUMINATE (PCYC-1130) trial, which showed longer progression-free survival for IMBRUVICA plus...

(STAT Plus) Oct 9, 2018 - A promising but controversial new approach to treating blood cancer could be in trouble in the earliest innings of human testing after Celgene pulled the plug on a trailblazing clinical trial. On Monday, Celgene terminated a Phase 1 study of CC-90002, which targets a protein that helps cancer cells stay out...